United States - English - NLM (National Library of Medicine)

boiron - vaccinia virus strain new york city board of health live antigen (unii: 4sv59689sk) (vaccinia virus strain new york city board of health live antigen - unii:4sv59689sk) - rx only* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

United States - English - NLM (National Library of Medicine)

a-s medication solutions - clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (unii: qsn5xo8zsu) (bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde in - boostrix is indicated for:     •    active booster immunization against tetanus, diphtheria, and pertussis in individuals aged 10 years and older,     •    immunization during the third trimester of pregnancy to prevent pertussis in infants younger than 2 months of age. do not administer boostrix to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of boostrix or after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine [see description (11)] . encephalopathy within 7 days of administration of a previous dose of a pertussis antigen-containing vaccine that is not attributable to another identifiable cause is a contraindication to administration of any pertussis antigen-containing vaccine, including boostrix. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to boostrix during pregnancy. healthcare providers are encouraged to register women by calling

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

sanofi pasteur - toxoide diftÉrico - toxoide diftÉrico....mÍnimo 30 ui / toxoide tetÁnico....mÍnimo 40 ui / antÍgenos de bordetella pertussis....: / toxoide pertÚsico....25 µg / hemaglutina filamentosa....25 µg / poliovirus (inactivado)....: / tipo 1 (mahoney)....40 ud / tipo 2 (mef-1)....8 ud / tipo 3 (saukett)....32 ud

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

glaxosmithkline biologicals s.a - toxoide de difteria - toxoide de difteria....2.5 lf - no menos de 2 ui / toxoide tetÁnico....5.0 lf - no menos de 20 ui / toxoide de pertusis....8 mcg / hemaglutinina filamentosa....8 mcg / pertactina....2.5 mcg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

sanofi pasteur limited - toxoide tetÁnico - toxoide tetÁnico....5 lf / toxoide de difteria....2 lf / hemaglutinina filamentosa....5.00 mcg / pertactina....3.00 mcg / toxoide de pertusis....2.50 mcg / fimbria tipo 2 y 3....5.00 mcg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

glaxosmithkline biologicals, s.a. - toxoide de pertusis - toxoide de pertusis....25 microgramos / hemaglutinina filamentosa....25 microgramos / pertactina (69kda proteÍna de membrana externa-prn)....8 microgramos / toxoide de difteria....mas de 30 ui / toxoide tetÁnico....mas de 40 ui / virus de polio inactivado tipo 1....40 du / virus de polio inactivado tipo 2....8 du / virus de polio inactivado tipo 3....32 du / hemophilus influenzae polisacárido capsular tipo b (bpr) ....10 migrogramos / toxoide tetÁnico (t)....aproximado 25 mcg.

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

glaxosmithkline biologicals s.a - toxoide de difteria - toxoide de difteria....30 unidades internacionales / toxoide tetÁnico....40 unidades internacionales / toxoide de pertusis....25 microgramos / hemaglutinina filamentosa....25 microgramos / poliovirus tipo 1 inactivado de antigeno d....40 unidades internacionales / polivirus tipo 2 de antigeno d....8 unidades internacionales / poliovirus tipo 3 antigeno d....32 unidades internacionales / polisacarido del haemophilus influenza tipo b....10 microgramos / conjugado al toxoide tetanico....25 microgramos / antigeno recombinante de la superficie del virus de hepatitis b (hbsag)....10 microgramos / pertactina....8 microgramos

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

glaxosmithkline biologicals s.a - toxoide de difteria (d) - toxoide de difteria (d)....min 30 iu / toxoide tetÁnico (t)....min 40 iu / toxoide pertussis (pt)....25 mcg / hemaglutinina filamentosa (fha)....25 mcg / pertactina (69kda proteÍna de membrana externa-prn)....8 mcg. / virus de polio inactivado tipo 1....40 du / virus de polio inactivado tipo 2....8du / virus de polio inactivado tipo 3....32 du / polisacarido capsular de haemophilus influenza tipo b (prp) conjugado con toxoide tetÁnico (tt)....10 mcg de prp y aprox 25 mcg de tt

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - neisseria meningitidis group a capsular polysaccharide tetanus toxoid conjugate antigen (unii: t4gyx3110d) (neisseria meningitidis group a capsular polysaccharide tetanus toxoid conjugate antigen - unii:t4gyx3110d), neisseria meningitidis group c capsular polysaccharide tetanus toxoid conjugate antigen (unii: zt89e5a103) (neisseria meningitidis group c capsular polysaccharide tetanus toxoid conjugate antigen - unii:zt89e5a103), neisseria meningitidis group y capsular polysaccharide tetanus toxoid conjugate antigen (unii: 4wan8pqk15) (neisseria meningitidis group y capsular polysaccharide tetanus toxoid conjugate antigen - unii:4wan8pqk15), neisseria meningitidis group w-135 capsular polysaccharide tetanus toxoid conjugate antigen (unii: l77ok410kw) (neisseria meningitidis group w-135 capsular polysaccharide tetanus toxoid conjugate antigen - unii:l77ok410kw) - menquadfi® is a vaccine indicated for active immunization for the prevention of invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. menquadfi is indicated for use in individuals 2 years of age and older. menquadfi does not prevent n. meningitidis serogroup b disease. severe allergic reaction to any component of the vaccine, or after a previous dose of menquadfi or any other tetanus toxoid-containing vaccine [see description (11) ]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to menquadfi during pregnancy. to enroll in or obtain information about the registry, call sanofi pasteur at 1-800-822-2463. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. there are no clinical studies of menquadfi in pregnant women. available human data on menquadfi administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. a developmental toxicity study in female rabbits administered a full human dose (0.5 ml) prior to mating and during gestation period revealed no evidence of harm to the fetus due to menquadfi (see animal data ). data animal data in a developmental toxicity study, female rabbits received a human dose of menquadfi by intramuscular injection on five occasions: 30 days and 10 days prior to mating, gestation days 6, 12 and 27. no adverse effects on pre-weaning development up to post-natal day 35 were observed. there were no vaccine-related fetal malformations or variations observed. risk summary it is not known whether menquadfi is excreted in human milk. data are not available to assess the effects of menquadfi on the breastfed infant or on milk production/excretion. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for menquadfi and any potential adverse effects on the breastfed child from menquadfi or from the underlying maternal condition. for preventive vaccines, the underlying maternal condition is susceptibility to disease prevented by the vaccine. safety and effectiveness of menquadfi have not been established in individuals younger than 2 years of age in the us. a total of 249 participants 65 years of age and older, including 71 participants 75 years of age or older, in study 4 received one dose of menquadfi [see adverse reactions (6.1) and clinical studies (14.1) ]. menquadfi recipients ≥ 65 years of age had lower gmts and seroresponse rates for all serogroups compared to menquadfi recipients 56 through 64 years of age [see clinical studies (14.1) ].

United States - English - NLM (National Library of Medicine)

a-s medication solutions - neisseria meningitidis group a capsular polysaccharide tetanus toxoid conjugate antigen (unii: t4gyx3110d) (neisseria meningitidis group a capsular polysaccharide tetanus toxoid conjugate antigen - unii:t4gyx3110d), neisseria meningitidis group c capsular polysaccharide tetanus toxoid conjugate antigen (unii: zt89e5a103) (neisseria meningitidis group c capsular polysaccharide tetanus toxoid conjugate antigen - unii:zt89e5a103), neisseria meningitidis group y capsular polysaccharide tetanus toxoid conjugat - menquadfi® is a vaccine indicated for active immunization for the prevention of invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. menquadfi is indicated for use in individuals 2 years of age and older. menquadfi does not prevent n. meningitidis serogroup b disease. severe allergic reaction to any component of the vaccine, or after a previous dose of menquadfi or any other tetanus toxoid-containing vaccine [see description (11) ]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to menquadfi during pregnancy. to enroll in or obtain information about the registry, call sanofi pasteur at 1-800-822-2463. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. there are no clinical studies of menquadfi